학술논문
234 - Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Document Type
Abstract
Author
Elsawy, Mahmoud; Chavez, Julio C.; Avivi, Irit; Larouche, Jean-François; Wannesson, Luciano; Cwynarski, Kate; Osman, Keren; Davison, Kelly; Rudzki, Jakob D.; Dahiya, Saurabh; Dorritie, Kathleen; Jaglowski, Samantha; Radford, John; Morschhauser, Frank; Cunningham, David; Garcia-Sancho, Alejandro Martin; Tzachanis, Dimitrios; Ulrickson, Matthew L.; Karmali, Reem; Kekre, Natasha; Thieblemont, Catherine; Enblad, Gunilla; Dreger, Peter; Malladi, Ram; Joshi, Namita; Wang, Wei-Jhih; Solem, Caitlyn T.; Snider, Julia Thornton; To, Christina; Kersten, Marie José
Source
In Transplantation and Cellular Therapy March 2022 28(3) Supplement:S190-S191
Subject
Language
ISSN
2666-6367